Systematic Prediction of Pharmacodynamic Drug-Drug Interactions through Protein-Protein-Interaction Network

被引:96
作者
Huang, Jialiang [1 ,2 ,3 ]
Niu, Chaoqun [1 ,2 ]
Green, Christopher D. [1 ]
Yang, Lun [4 ]
Mei, Hongkang [3 ]
Han, Jing-Dong J. [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Biol Sci, Max Planck Partner Inst Computat Biol, Key Lab Computat Biol, Shanghai, Peoples R China
[2] Chinese Acad Sci, Ctr Mol Syst Biol, Inst Genet & Dev Biol, Beijing, Peoples R China
[3] GlaxoSmithKline Res & Dev China, Integrated Platform Sci, Bioinformat, Shanghai, Peoples R China
[4] GlaxoSmithKline, Computat Biol, Systemat Drug Repositioning, Philadelphia, PA USA
基金
中国国家自然科学基金;
关键词
PHARMACOLOGY; DISEASE;
D O I
10.1371/journal.pcbi.1002998
中图分类号
Q5 [生物化学];
学科分类号
070307 [化学生物学];
摘要
Identifying drug-drug interactions (DDIs) is a major challenge in drug development. Previous attempts have established formal approaches for pharmacokinetic (PK) DDIs, but there is not a feasible solution for pharmacodynamic (PD) DDIs because the endpoint is often a serious adverse event rather than a measurable change in drug concentration. Here, we developed a metric "S-score'' that measures the strength of network connection between drug targets to predict PD DDIs. Utilizing known PD DDIs as golden standard positives (GSPs), we observed a significant correlation between S-score and the likelihood a PD DDI occurs. Our prediction was robust and surpassed existing methods as validated by two independent GSPs. Analysis of clinical side effect data suggested that the drugs having predicted DDIs have similar side effects. We further incorporated this clinical side effects evidence with S-score to increase the prediction specificity and sensitivity through a Bayesian probabilistic model. We have predicted 9,626 potential PD DDIs at the accuracy of 82% and the recall of 62%. Importantly, our algorithm provided opportunities for better understanding the potential molecular mechanisms or physiological effects underlying DDIs, as illustrated by the case studies.
引用
收藏
页数:9
相关论文
共 31 条
[1]
Drug interactions in oncology [J].
Beijnen, JH ;
Schellens, JHM .
LANCET ONCOLOGY, 2004, 5 (08) :489-496
[2]
Role of systems pharmacology in understanding drug adverse events [J].
Berger, Seth I. ;
Iyengar, Ravi .
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE, 2011, 3 (02) :129-135
[3]
Network analyses in systems pharmacology [J].
Berger, Seth I. ;
Iyengar, Ravi .
BIOINFORMATICS, 2009, 25 (19) :2466-2472
[4]
Drug target identification using side-effect similarity [J].
Campillos, Monica ;
Kuhn, Michael ;
Gavin, Anne-Claude ;
Jensen, Lars Juhl ;
Bork, Peer .
SCIENCE, 2008, 321 (5886) :263-266
[5]
Tricyclic antidepressant pharmacology and therapeutic drug interactions updated [J].
Gillman, P. K. .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (06) :737-748
[6]
The human disease network [J].
Goh, Kwang-Il ;
Cusick, Michael E. ;
Valle, David ;
Childs, Barton ;
Vidal, Marc ;
Barabasi, Albert-Laszlo .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (21) :8685-8690
[7]
INDI: a computational framework for inferring drug interactions and their associated recommendations [J].
Gottlieb, Assaf ;
Stein, Gideon Y. ;
Oron, Yoram ;
Ruppin, Eytan ;
Sharan, Roded .
MOLECULAR SYSTEMS BIOLOGY, 2012, 8
[8]
Network pharmacology: the next paradigm in drug discovery [J].
Hopkins, Andrew L. .
NATURE CHEMICAL BIOLOGY, 2008, 4 (11) :682-690
[9]
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources [J].
Huang, Da Wei ;
Sherman, Brad T. ;
Lempicki, Richard A. .
NATURE PROTOCOLS, 2009, 4 (01) :44-57
[10]
Drug interaction studies: Study design, data analysis, and implications for dosing and labeling [J].
Huang, S-M ;
Temple, R. ;
Throckmorton, D. C. ;
Lesko, L. J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) :298-304